Sygnature Discovery

SEPTEMBER 11, 2024

Compound Screening Fragment Based Drug Discovery supported by Crystallography or SPR & MST. Covalent compound binding by mass spectrometry. Protein Characterisation & Quality Control Mass spectrometry – intact protein, peptide mapping and native. NMR, FIDA, ITC, SEC-MALS and FSEC. SPR, DLS, MST, FTSA and CETSA.

Science 52

Science Compound Screening Protein Expression RNA 52

Drug Target Review

NOVEMBER 1, 2023

We are part of the ICR’s PhD-student programme, which is exciting, because with PhD-student projects we have the ability to probe the more academic questions related to our drug discovery science. We need to build the assays that we need for compound screening. We are involved from a very early stage once a target is validated.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

KIF1A

AUGUST 28, 2024

KIF1A.ORG’s Chief Science Officer Dr. Dylan Verden will provide an overview of current areas of KAND therapeutic… Tuesday, September 24, 2024 5:00 pm – 6:00 pm Online via Zoom [link] ASO therapy: Positive Clinical Outcomes Observed We are thrilled to announce the publication of the **first-ever KAND ASO study** !

Therapies 52

Therapies Compound Screening Research Treatment 52

The ChEMBL-og

APRIL 16, 2024

The data set of chemical probes was retrieved from 1) the chemicalprobes.org website and filtered for probes that were assigned an In Vivo Rating or In Cell Rating of 3 stars or more, and from 2) probes-drugs.org by filtering for the subsets “SGC Probes” and “Open Science Probes”. Data set retrieved on 09/02/2024.

Clinical Trials 108

Clinical Trials FDA Cell Based Assays Compound Screening 108